부산대학교 도서관

Background. The efficacy of local consolidative therapy (LCT) for oligometastatic non-small-cell lung cancer (NSCLC) has been reported. However, the feasibility and prognostic impact of LCT following immunotherapy have been unknown. We herein report a patient who underwent immunotherapy followed by LCT for oligometastatic NSCLC. Case. A 66-year-old male former smoker presented with stage IV lung cancer in the right upper lobe and an oligometastasis in the right adrenal gland. The patient underwent chemoimmunotherapy, which resulted in a partial response. Right upper lobectomy with mediastinal lymph node dissection followed by stereotactic body radiotherapy (SBRT) with a CyberKnife for a right adrenal metastasis was planned as LCT. The surgery was provided 86 days after the chemoimmunotherapy due to the requirement of steroid therapy for arthritis as an immune-related adverse event (irAE). SBRT with a CyberKnife was conducted 58 days after the surgery. He has been alive without disease relapse for one year since the initiation of treatment. Conclusion. In general, there are multiple treatment choices, combinations, and orders for LCT; therefore, accumulating individual case experiences and sharing information on the outcomes is crucial. SBRT with a CyberKnife is one choice for LCT for oligometastasis of the adrenal gland. Care should be taken to complete surgery as LCT in patients with irAEs requiring steroid therapy.